NCT02227667

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the patient and cancer. MEDI4736 is a type of medication called an antibody. Antibodies are normal proteins in the body that help fight infections and possibly cancer. MEDI4736 is a special type of an antibody produced in a laboratory. MEDI4736 works by blocking a specific protein called the Programmed Death Ligand-1 (PDL-1), located on tumor cells.

Conditions

• Advanced Colorectal Cancer

Interventions

Type	Name	Description
DRUG	MEDI4736	Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.

Timeline

• Start date: 2014-12-02
• Primary completion: 2020-06-29
• Completion: 2020-06-29
• First posted: 2014-08-28
• Last updated: 2021-06-18
• Results posted: 2021-06-18

Locations

1 site across 1 country: United States